Mereo BioPharma Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Mereo BioPharma Group has a total shareholder equity of $78.7M and total debt of $4.9M, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are $96.1M and $17.5M respectively.
Anahtar bilgiler
6.3%
Borç/özkaynak oranı
US$4.93m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$87.43m |
| Eşitlik | US$78.65m |
| Toplam yükümlülükler | US$17.48m |
| Toplam varlıklar | US$96.13m |
Son finansal sağlık güncellemeleri
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: MREO's short term assets ($93.9M) exceed its short term liabilities ($15.5M).
Uzun Vadeli Yükümlülükler: MREO's short term assets ($93.9M) exceed its long term liabilities ($2.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: MREO has more cash than its total debt.
Borcun Azaltılması: MREO's debt to equity ratio has reduced from 33.4% to 6.3% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: MREO has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: MREO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.5% each year